Scientists Create Non-Psychedelic Compound with Same Anti-depressant Effect
Retrieved on:
Wednesday, September 28, 2022
Mental Health, Research, Other Natural Resources, Other Health, Alternative Medicine, Health, Other Science, Science, Natural Resources, Tao, Selective serotonin reuptake inhibitor, National, Depression, Human, THP, LSD, DARPA, Patient, UNC, 5-HT2A, R-69, Anxiety, Research, Hallucination, Psychiatry, Eugene Higgins, Mouse, Serotonin, Doctor of Philosophy, DMT, Â, UCSF, Duke, Ketamine, Michael Hooker, FDA, MD, UNC School of Medicine, University of North Carolina at Chapel Hill, Stanford University, AstraZeneca, Permeability, Tony Hawk's Pro Skater 1 + 2, Department, Mount Sinai, Brain, Zehnder Confair, Psilocybin, Esketamine, Ellman, Neurochemistry, Defense, University of California, San Francisco, Protein, Cell, N,N-Dimethyltryptamine, Substance abuse, SSRI, Department of Defense Office of Inspector General, Multimedia, Neuron, Pharmaceutical industry, Yale University, Medicine, Pharmacology, Chemistry, Nature
Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
Key Points:
- Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
- Other scientists speculate that if the trip could be eliminated from such drugs, then only the therapeutic effects might remain.
- We were basically running a chemistry experiment to see if we could create a compound to activate 5-HT2A.
- It would be a game changer to create a one-dose, long-acting therapy to help people with treatment-resistant depression and other conditions.